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Abstract 
Introduction. Low functioning variants of 5HTTLPR have been associated to an increased risk of 
depression in subjects who experienced stressful events, to altered cognitive functioning  and 
decisional processes, and functional and structural neural patterns. Contrasting evidence is available 
up to now in Eating Disorders (ED), and no study has evaluated the polymorphism effect on brain 
connectivity according to graph theory in Anorexia Nervosa (AN).  
Methods. We recruited up to 735 patients with life-time history of AN or bulimia nervosa (BN) 
according to DSM-IV criteria and up to 241 healthy controls (HC) for the assessment of the 
association between 5HTTLPR polymorphism and ED. We merged our Biobank data from 
BIO.Ve.D.A. and meta-analyzed 22 former studies. Patients underwent a structured diagnostic 
interview for present or life-time ED, an interview for presence and severity of stressful events, 
Edinburgh Handedness Inventory, Wisconsin Card Sorting Test, Trail A making test, Trail B making 
test, Iowa Gambling Task, Cognitive Bias Task, psychopathology rating scales for ED and general 
symptoms. Finally patients with AN and HCs underwent a Magnetic Resonance; their brains’ 
connectivity integration and segregation measures were then measured with Graph Analysis Toolbox, 
according to 5HTTLPR polymorpshim. 
Results. Our results from a meta-analysis including data from BIO.Ve.D.A. and 22 previous studies, 
suggest that 5HTTLPR polymorphism does not have a role per se in determing ED onset. However 
it may moderate the effect of SEs in increasing the risk of ED onset, and the influence of SEs on ED 
severity, anxious, depressive and obsessive symptoms. When we tested both a multiplicative and an 
additive model, which is considered to be more representative of a real-world gene by environment 
interaction, such a 5HTTLPR by SE interaction was not confirmed instead. S allele was associated 
with worse performance at Cognitive Bias Task and Trail Making B, and with increased ED 
psychopathology, general psychopathology, anxious, depressive, and obsessive symptoms. Finally S 
allele was associated with decreased segregation measures at brain connectivity analysis according 
to graph theory compared with L allele in AN; this was an opposite association compared with healthy 
controls who had higher modularity associated with S allele instead. 
Conclusions. 5HTTLPR polymorphism does not seem to be a causal factor of ED per se, but it seems 
to play a role in moderating the role of stressful events in increasing ED risk. Such a moderation 
however did not reflect a gene by environment interaction according to either a multiplicative or 
additive model. S allele was associated with higher psychopathology scores, and worse 
neuropsychological functions in AN, and with a disrupted segregation measures of brain signal 
connectivity compared to HCs.  
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1. 5HTTLPR POLYMORPHISM IN PSYCHIATRY 
Psychiatric disorders pathogenesis is well represented by a multifactorial model, including genetic, 
and environmental factors. As regards genetics, increasing body of evidence has focused on 
5HTTLPR polymorphism. 5HTTLPR is a 5’ regulatory promoter region on chromosome 17 that has 
been modelled as being bi-allelic in nature depending on a 44bp deletion or insertion, with the S allele 
being low functioning, and the L allele being high functioning (fig. 1) (1). Moreover, a tri-allelic 
model has been illustrated, with the Lg (an L allele with Gre placing A in its SNP sequence) allele 
functioning equivalent to the S allele(2, 3). This polymorphism has been described having different 
distributions in different ethnicities (4), has been studied in several different psychiatric disorders, 
and in general population. However contrasting results emerged, which we now focus on, with this 
brief introduction about the role of 5HTTLPR in psychiatry.  
Several historically grounded reasons and more actual scientific evidence support the potential 
clinical impact of 5HTTLPR polymorphism. The monoaminergic theory of depression which 
originated from clinical observations in 1950s and which has then been supported by several pieces 
of both clinical and pre-clinical evidence(5), suggests a central role of serotonin in pathogenesis of 
major depressive disorder (MDD) (6) together with other monoamines (7). Thus several authors have 
focused on the possible role of 5HTTLPR polymorphism in MDD. 5HTTLPR short allele 
homozygosity has been associated with increased risk of depression(8) compared to long allele 
homozygosity in females, and the same results have been confirmed in a recent meta-analysis (9) 
including  3392 cases and 5093 controls from 23 studies (S allele homozygosity; OR=1.33, 95%CI 
1.19-1.48 - S allele presence; OR=1.16, 95%CI 1.08-1.23). Also, S allele has been associated with 
earlier MDD onset in a Japanese population(10), and notably long allele has been associated with 
faster response to sertraline in elderly patients affected by MDD(11), and better response to 
psychotherapy in children with anxiety disorders(12). The same recent meta-analysis mentioned 
above has also associated low functioning 5HTTLPR polymorphism with an increased risk of alcohol 
dependence(9)  (S allele homozygosity; OR=1.18, 95%CI 1.01-1.38 - S allele presence; OR=1.26, 
95%CI 1.01-1.23). Furtherly widening the spectrum of psychiatric conditions whose risk could be 
increased by being an S-allele carrier, also antisocial and borderline personality disorders have been 
reported to be more frequent in S allele carriers in low-income countries(13). In patients with Bulimia 
Nervosa (BN) symptoms short allele has been associated with novelty(14) and sensation seeking, 
insecure attachment(15) and dissocial behavior(16) in presence of life-time physical or sexual abuse. 
Also, within patients with BN, harm avoidance has been reported higher in those patients with S allele 
compared to those without it(17). Short allele genotype has also been associated with antisocial 
behaviors(18) in a meta-analysis of studies including human samples, and with aggressive behaviors 
in children as well(19). Moreover, property offending behaviors under the effects of cannabinoids 
has been described in African American females who carried 5HTTLPR short allele(20). Finally, 
higher harm avoidance, alongside with higher scores at Beck Depression Inventory have been 
described in young subjects with excessive internet use(21).  Beyond diagnostic entities, 5HTTLPR 
polymorphism has also been associated with dimensional personality and temperament 
characteristics in general population. In a community sample S allele has shown higher avoidant 
personality scores at International Personality Disorder Examination(22). Moreover, in a sample of 
169 healthy females with no psychiatric condition, anxiety, depression, hopelessness, guilt, hostility, 
aggression, presence of neurotic symptoms, self-directedness scores, and affective temperaments 
carrying a depressive component have been associated with S allele, even after controlling for 
age(23). Finally, in 139 Caucasian psychiatrically healthy women, hyperthymic temperament as 
measured by TEMPS-A, the least associated with affective disorders(24), was the only temperament 
domain which was not associated with S allele(25).  
However despite such a body of evidence suggesting a role of low functioning 5HTTLPR in severe 
psychiatric disorders, several negative results have not confirmed a role of this polymorphism in 
mental illness. For example, in Japanese population the association between S allele and increased 
depression risk has not been confirmed(10). Beyond depression, considering the wider affective 
disorders spectrum, no association has been described in a large European multicenter case-control 
study involving 539 unipolar affective disorders, 572 bipolar patients, and 821 control(26). 
Additionally, neither a mediator role on response to psychotherapy has been replicated for 5HTTLPR, 
even if negative results were limited to childhood anxiety disorders(27). Furthermore, beyond 
depression and affective disorders, in a meta-analysis we published in World Journal of Biological 
Psychiatry in 2016 and that we are presenting in the following chapter of the present final dissertation, 
when we accounted for ethnicity related heterogeneity, and for publication bias, neither Eating 
Disorders (ED) were associated with the short allele of the promoter of the gene for the serotonin 
transporter(28).  
Based on such a body of conflicting evidence, we have investigated the role of  5HTTLPR in ED as 
a risk factors per se, its interaction with stressful events according to a gene by environment model,  
its effects on neuropsychological functions within ED, and the possible neural pathways underpinning 
such functions in a sample of patients with AN. 
  
1. 5HTTLPR POLYMORPHISM IN EATING DISORDERS 
(Original manuscript has been published in World J Biol Psychiatry. 2016 Jun;17(4):244-57) 
2.1 INTRODUCTION 
5-HTTLPR polymorphism is by far the most studied polymorphism in psychiatry, and growing 
interest is focusing on its role in eating disorders (ED) as well. 5HTTLPR is a 5’ regulatory promoter 
region on chromosome 17 that has been modelled as being bi-allelic in nature depending on a 44bp 
deletion or insertion, with the S allele being low functioning, and the L allele being high functioning 
(fig. 1) (1). Moreover, a tri-allelic model has been proposed,with the Lg (an L allele with Gre placing 
A in its SNP sequence) functioning equivalent to the S allele. Low functioning variants of this 
triallelic polymorphims have been associated to an increased risk of depression in subjects who 
experienced stressful events(8), to altered cognitive functioning(29) and decisional process, and to 
precise functional and structural neural patterns. Despite some former meta-analyses suggesting an 
association between the short/low functioning 5HTTLPR allele (S) and anorexia nervosa (AN), 
contrasting evidence is available up to now. Several studies have investigated the relationship 
between AN, BN and ED and 5HTTLPR. However, only one focused on binge ED, and only two 
compared patients affected by AN with an obese sample. These studies have partially been meta-
analysed with literature searches conducted up to July 2008 (30) and October 2009(31). However, 
more individual studies have explored this area since then, after 2009 (last search date from previosu 
authors). 
The aim of this part of the study is to meta-analyze studies that investigated the association between 
5HTTLPR polymorphism and ED, merging available data in literature and data from the ‘Biobanca 
Veneta per i Disturbi Alimentari’ (BIO.VE.D.A.) 
2.2 METHODS 
Participants, DNA sampling and analysis. The ‘Biobanca Veneta per i Disturbi Alimentari’ 
(BIO.VE.D.A.) sample included 735 patients with a lifetime history of AN and/or BN according to 
DSM-IV criteria, and 241 HC. Patients were recruited in five Eating Disorder Units of the Veneto 
region, Italy. The BIO.VE.D.A. project is funded by the Veneto Region and aims to create a genetic 
biobank for ED (30). Inclusion criteria were a life-time diagnosis of AN or BN according to DSM-
IV (32), age >14 years old, patients’ and parental (if less than 18 years old) informed consent. The 
study was approved by the local hospital Ethic Committee. Exclusion criteria were organic 
comorbidity or major psychiatric comorbidity (bipolar disorder, schizophrenia, major depressive 
disorder). After informed consent, all participants underwent a saliva or blood sample. Genomic DNA 
was extracted from 200ml of whole peripheral blood, using a High Pure PCR Template Preparation 
Kit (Roche Diagnostics GmbH), or from 500ml of saliva using an Oragene DNA/saliva Kit (DNA 
Genotek Inc.) according to the manufacturer’s instructions. The 5-HTT promoter region was 
amplified from genomic DNA to discriminate between the L- and S-alleles (rs4795541). Primer 
sequences were designed using Primer 3 software (http://frodo.wi.mit.edu/) (forward: 
CAACTCCCTGTACCCCTCC T and reverse: GTGCAAGGAGAATGCTGGAG). This reaction 
produced a fragment of 297 bp for the long L allele and a fragment of 254 bp for the short S allele. A 
total of 200ng of genomic DNA was amplified using 12.5ml of prealiquoted ReddyMix PCR Master 
Mix (Thermo Fisher Scientific, Milan, Italy), 10 X DMSO and 0.4mcM of each primer, in a total 
volume of 25ml. Cycling conditions were: 1 cycle at 94°C for 4min, followed by 37 cycles at 94°C 
for 1min, at 61°C for 1min and at 72°C for 1min. To genotype the rs25531 the amplification was 
followed by a restriction digestion. A total of 7ml of PCR product was digested at 37°C for 2h with 
5U of MspI (New England BioLabs, Celbio, Milan, Italy), which recognises the sequence 50-C/CGG-
30. Fragments were separated on acrylamide gel at 10% (45min at 200V). The LA allele produces 
fragments of 257 and 39 bp, while the Lg allele produces fragments of 174, 84 and 39 bp. 
Search strategy. We conducted an electronic literature search in PubMed from database inception 
until 1 April 2015 for studies investigating 5HTTLPR biallelic or trialleic genotype or alleles 
frequencies in ED, with or without a control group. Controlled vocabulary terms (MeSH) and the 
following keywords were used in the search strategy: ((‘‘Anorexia Nervosa’’[Mesh]) OR (‘‘Bulimia 
Nervosa’’[Mesh]) OR (‘‘Eating Disorders’’[Mesh]) OR (‘‘Binge-Eating Disorder’’[Mesh]) AND 
(serotonin transporter OR 5HTTLPR OR 5-HTTLPR)). Reference lists of included articles and those 
relevant to the topic were hand-searched for identification of additional potentially relevant articles.  
Study selection. Included were only studies that: (1) included patients affected by ED according to 
DSM-IV criteria and (2) reported 5HTTLPR genotype or allele frequencies in patients affected by 
ED, and a control group, if present. Both biallelic and triallelic modelled studies were analysed. 
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) criteria (33) were 
used for the quality assessment of included studies. Previous reviews and meta-analyses were fulltext 
read to identify further studies.  
Data extraction and statistical analysis. Two authors independently extracted data from the selected 
studies into a standardised Microsoft Excel spreadsheet. Any disagreement was resolved by 
consensus. The following information was extracted: (i) study population characteristics (e.g. sample 
size, demographics, diagnostic criteria and subtype of AN or BN, comorbidities, medications, 
anthropometric data); (ii) biallelic or trialleic genotype or alleles frequencies in patients and controls; 
(iii) quality indicators used for the STROBE assessment; and (iv) Hardy–Weinberg equilibrium 
(HWE). Whenever studies had the same authors or affiliation or close publication year, we contacted 
authors to verify data were not referring to the same sample. Whenever genotype or allele frequencies 
were not available, we contacted authors to ask for unpublished data. Furthermore, we extracted data 
from a previous meta-analysis (34), reporting data not available in original papers. We ran the 
following comparisons within patients and within controls: (1) triallelic low-functioning genotype 
frequency (containing S or Lg) vs. high-functioning genotype (LaLa); (2) biallelic low-functioning 
genotype (SS or SL) vs. high-functioning (LL); (3) triallelic low-functioning allele frequency (S and 
Lg) vs. high-functioning allele frequency (La); (4) biallelic low-functioning allele frequency (S) vs. 
high-functioning allele frequency (L). Additionally, comparing ED, AN and BN patients with the 
respective healthy control group, we ran the following comparisons: (5) biallelic low-functioning 
genotype frequencies (SS or SL), including recessive model testing for the low-functioning allele; (6) 
biallelic low-functioning allele frequencies (S); (7) triallelic low-functioning genotype (containing S 
or Lg); and (8) triallelic lowfunctioning allelic frequencies (S and Lg). When an obese sample was 
used as a control group(7, 9), we compared it separately to the ED samples. Moreover, we tested also 
dominant models for the low-functioning allele in ED, AN and BN vs. HC. Finally we compared the 
bi-allelic model vs. triallelic model, reporting differences in frequencies from studies providing both 
bi-allelic and triallelic data. Grouping of SS and SL was based on the presumed dominant role of the 
S allele of 5HTTLPR polymorphism. We meta-analysed comparisons reported in at least two studies, 
in order to provide the maximum number of meta-analyzable outcomes. The meta-analysis was 
performed using Review Manager(35) Version 5.1 for Windows. When combining studies, the 
random effects model (36) was used to account for study heterogeneity. For dichotomous data, odds 
ratio (OR) with its 95% confidence interval (CI) was used. Study heterogeneity was measured using 
the chi-squared and I-squared statistics, with chi-squared p>0.05 and I-squared>50% indicating 
significant heterogeneity (37). If I-squared>50% a sensitivity test was performed, where each study, 
one at a time, was excluded from the overall OR calculation to examine if any single study contributed 
significantly to the overall result. Furthermore, since there is evidence of different distributions of 
5HTTLPR in specific ethnicities, e.g. higher S allele frequencies in Japanese populations compared 
to Caucasian populations, we ran a sensitivity analysis with studies including other than Caucasian 
populations. Finally, funnel plots were inspected visually to assess the possibility of a publication 
bias. We included Bio.Ve.D.A. group data in the meta-analysis. HWE was tested in each study 
separately with both chi-squared test and relative excess heterozygosity test (REH) (38). Finally, we 
tested the pooled REH from all included studies using a random effect model, which is a more 
appropriate tool than the chi-squared test to test HWE in meta-analyses(38).  
2.3 RESULTS 
Results from this part of the project have been published on World Journal of Biological 
Psychiatry(28). 
BIO.VE.D.A. Data. The BIO.VE.D.A. sample includes 735 patients affected by ED and 241 HC. 
Among ED, 526 were affected by AN lifetime, 341 by BN lifetime. Demographic features, genotype 
and allele frequencies are displayed in Table 4. No differences were found in both biand tri-allelic 
allele frequencies, or in genotype frequencies, between ED, AN, BN and HCs, or between different 
EDs.  
Hardy–Weinberg equilibrium and relative excess heterozygosity test. All included studies were 
consistent with HWE and REH (38) according to random effects model; only one study(39)  reported 
data from a sample with a lower-than-expected l/l frequency.  
Included studies. We included BIO.VE.D.A. data and data from 21 studies, according to the flow 
chart shown in Figure 2. We excluded one study because it allowed for subclinical participants; 
however, this study was included in a previous meta-analysis(31). The main features of the 22 
included studies are summarised in Table 1. Altogether, 16 studies compared patients affected by ED 
with non-affected controls; six studies did not include a control group. Of the 16 control groups, 12 
studies used HCs, two included obese subjects, one underweight subjects one normal eaters, one 
healthy sisters (40), and one parents (41). All studies defined ED according to DSM-IV criteria. 
Sixteen of the 22 studies used a biallelic model, six also used a triallelic. The quality of the included 
studies is available upon request. 
Analyses within patients and within controls. Results of the meta-analyses within patients and within 
controls are reported in Table 2. Within patients and within controls, low-functioning genotypes were 
more frequent than high-functioning ones (ED vs. controls, P<0.0001). Within patients and within 
controls, high-functioning alleles were more frequent than low-functioning ones in the biallelic 
model. This result held true even in a leaveone-out sensitivity analysis, which based on funnel plot 
inspection excluded Matsushita et al. from the analysis. However, adopting the triallelic model, no 
significant difference emerged between low- and highfunctioning allele frequencies. Comparing the 
two models, only including studies using both the biallelic compared with the triallelic model 
included 9.9% more low-functioning genotype and 13.7% more low-functioning alleles.  
Analyses comparing patients vs. controls. All results of the meta-analyses comparing patients with 
control groups are reported in Table 3. Low-functioning genotype frequencies in patients groups, 
with both biand tri-allelic models, did not differ from control groups (Figure 3). Furthermore, in both 
bi- and triallelic models, low-functioning allele frequencies in ED and in BN patients (biallelic only), 
were not different from control groups. Low-functioning allele frequencies in AN, in the Biallelic 
model, were significantly higher than in control groups (P=0.03). However, we removed one clearly 
outlying study (42) from the analysis based on funnel plot inspection, and as the patient group was 
more than 3 times smaller than the control group; the result became non-significant (P=0.09) (Figure 
4). Finally, we did not find that a dominant model significantly explained the group difference 
between AN (P=0.13, after removing Matsushita et al,  BN (P=0.85), or ED (P=0.37), vs. HC.  
ED patients vs. obese patients. Only two studies compared patients affected by ED with patients 
affected by obesity. Low-functioning genotype and allele frequencies were not significantly different 
between the two groups (genotype P=0.37; allele P=0.40). 
2.4 DISCUSSION 
Several lines of evidence show that an abnormal functional activity of the 5-HT system might affect 
satiety, anxiety and mood disorders. However, according to our data, 5HTTLPR polymorphism did 
not appear to have any direct additive effect on the risk of developing ED. Thus, although two 
previous meta-analyses(30, 31) reported significant associations between the low-functioning allele 
of 5-HTTLPR polymorphism and the risk of having AN, the newly accumulated evidence shows 
contrasting evidence about the role of this polymorphism in ED – including AN. Similarly to what 
has been observed in other psychiatric disorders (41-44), an additive effect of a single polymorphisms 
is not a valid model to explain the pathogenesis of ED. Therefore, studies exploring interactive effects 
are needed. In the present study, a comparison between patients vs. controls was performed to re-test 
previously investigated associations with updated evidence. Both in the BIO.VE.D.A. data and in our 
meta-analysis, we found no significant difference in low-functioning genotype and allele frequencies 
between ED and controls. Regarding BN, a previous meta-analysis (14) pointed out that the 
relationship between the serotonin transporter gene polymorphism variance and BN was still 
controversial. In our meta-analysis, we added not only one more study to the pooled data, but we 
added the BIO.VE.D.A. data as well, including evidence from the largest sample published up to 
now. Our data confirm, like the previous findings (30), the absence of any difference in the 5HTTLPR 
polymorphism distribution in ED vs. controls. This finding seems to rule out serotonin transporter 
polymorphism as a causal factor per se in the ED pathogenesis. Another unique contribution of this 
meta-analysis is the comparison of allele and genotype frequencies between patients with ED and 
individuals affected by obesity. This comparison also showed no difference between the two groups, 
suggesting no relationship between BMI and 5HTTLPR polymorphism, as previously reported in a 
psychiatric sample. However, we acknowledge that a meta-analysis including only two studies is very 
limited, so more studies are needed in this area. Furthermore, more studies should investigate the link 
between serotonin transporter polymorphism and BMI, in both healthy and psychiatrically ill 
subjects. We also tried to investigate samples affected by BED in our analysis, but to our knowledge 
only one study (43) has investigated serotonin transporter polymorphism in that population, 
precluding any meta-analytic assessment. The second part of our analysis was to evaluate the impact 
of the triallelic model in comparison to the biallelic model. Since the biallelic model classifies Lg 
alleles as high-functioning, which are actually lowfunctioning, a triallelic model is preferred since it 
better describes the ‘‘functional’’ distribution of the different alleles and genotypes. To date, only 
three studies in six studies used a triallelic model. Finally, our analyses within patients and within 
controls add to the available knowledge about the epidemiological distribution of the 5HTTLPR 
genotype, showing that low-functioning genotypes were significantly more frequent than high-
functioning genotypes in both ED and controls. This finding could be due to the fact that low-
functioning genotypes include two out of three (SS+SL vs. LL in biallelic model) and five out of six 
(SS+SLa+SLg+LgLg+LgLa vs. LaLa in triallelic model) possible combinations, respectively. 
However, other reasons could also play a role, including pleiotropic effects of the 5HTTLPR 
polymorphism and unknown advantages of a low-functioning 5HTTLPR genotype under certain 
conditions. More research in this area is needed to further clarify this finding and its potential 
implications. The present study has both strengths and limitations that need to be taken into 
consideration when interpreting its results. First, the BIO.VE.D.A. biobank provides the largest 
sample of patients affected by ED (compared to a healthy control group) that has been investigated 
regarding the polymorphism of the serotonin transporter gene. Furthermore, BIO.VE.D.A. data agree 
with the results of the meta-analysis (considering the sensitivity analysis invalidating the association 
of the S allele and S or SL genotype with ED compared to controls). Moreover the BIO.VE.D.A. 
sample is free from major psychiatric comorbidities (bipolar disorder, schizophrenia, major 
depressive disorder), removing the possibility of potential biases due to other major psychiatric 
disorders. Table 1 presents data showing how previous studies often did not control for depressive 
disorders that are frequently encountered in patients with ED. Thus, authors firmly promote multi-
centric collaborations involving national health services both within and among countries. Second, 
with seven additional studies published in the last 6 years since the last meta-analyses, this meta-
analysis increased the sample size from 2,105 to 3,736 patients and from 2,032 to 2,707 controls. 
Third with our search we also explored the relationship with BED and obesity, pointing out the need 
for more studies in order to build some reliable evidence on the relationship between 5HTTLPR, 
BED, and obesity. Fourth, we stressed the need for more Asian studies, since compared to Caucasians 
the S allele seems more frequent in Asian people, in particular in the Japanese(44, 45). Fifth, 
compared to the meta-analysis by Lee and Lin(30), we increased the sample size of BN from 395 to 
824 patients, without mixing in sub-clinical samples, as others (31) did. While we agree that a 
dimensional investigation is necessary to explain the relationship between symptoms and genes as 
proposed by Calati(31), we suggest that specifically designed studies are needed to provide consistent 
evidence on this dimensional aspect of ED. Conversely, mixing in minimally symptomatic subjects 
with ES is not helpful, adding more noise than clarifying dimensionality aspects. Moreover, our paper 
differs from Calati, in that we only metaanalysed studies with comparisons between patients and 
control groups, instead of building a virtual control group for studies without concurrently collected 
control groups. Finally, our results have been confirmed and cited by a more recent MA focusing on 
a different subject, but coming to identical conclusions in a supplementary analysis parallel to its 
main object of interest (5HTTLPR and stressful events in ED(46). The main limitations of the present 
study were: (1) the lack of studies controlling for comorbid anxiety, mood disorders, and suicidal 
behaviour, all possibly associated with 5HTTLPR polymorphism(47, 48); (2) few studies included 
Asian patients, precluding a better understanding of the relationship between 5HTTLPR 
polymorphisms and ED in that ethnic group; (3) there were frequent definitions of control groups as 
not being affected by ED, without clear exclusion of other organic or psychiatric diseases; (4) there 
was a lack of studies to date reporting data using the new diagnostic criteria using DSM-5(49),  and 
(5) only two studies compared ED with obesity, which renders these results preliminary. In 
conclusion, the present meta-analysis did not confirm results from previous single studies 
hypothesising an additive major role of 5HTTLPR polymorphism for the risk of developing an ED. 
However, data provided by the present meta-analysis cannot rule out a possible small additive effect 
of 5-HTTLPR (that could be demonstrated only in very large samples), or an interactive effect. Thus, 
future studies should be designed to overcome the limitations of available studies, including a better 
definition of healthy control groups, the use of triallelic models, assessment of the effects of 
psychiatric comorbidity and ethnic differences, as well as providing data about possible 
environmental risk factors – such as stressful and traumatic events – that might interact with 5-
HTTLPR polymorphism in increasing the risk for developing an ED. 
  
 
 
 
  
 
  
 
 
Figure 1. Chromosome 17. 
 Fig 2. PRISMA flow diagram of study selection process in 5HTTLPR and Eating Disorders meta-analysis. 
 
Fig 3. Bi-allelic low functioning genotype frequency in anorexia nervosa vs healthy controls. 
  
Fig 4. Bi-allelic low functioning allele frequency in anorexia nervosa vs healthy controls. 
  
3. STRESSFUL EVENTS AND 5HTTLPR IN EATING DISORDERS 
3.1 INTRODUCTION 
Beyond genetics, environmental factors have a role in all medical conditions, and in particular in 
psychiatry where reality perception, interpersonal attitude, impulsivity, avoidance, perseverance, 
cognitive performance, behavior, resilience and thought processes can all interact with environment 
in a reciprocal way, and determine one individual’s subjective perception of traumatic or non-
traumatic events. Stressful events (SE)  have been extensively studied in their role of potentially 
determining  several psychiatric disorder, and have been associated with major depressive disorder 
(MDD)(50, 51), and bipolar disorder (BD) (51) among others. Several hypotheses have been 
formulated about the putative mechanism underlying the link between SE and psychiatric disorders. 
Among other psychological factors, attachment style has been proposed as a mediator between 
traumatic events and development of depression, and has also been proposed as a potential therapeutic 
target in the pathogenetic pathway to MDD (52). From a biological perspective, early traumatic 
events may influence the onset of both MDD(53) and BD(54) through an epigenetic mechanism, 
which in turn may reciprocally interact with the hypothalamic-pituitary-adrenal axis dysregulation 
which is known in MDD and BD. 
Regardless SE and traumatic events, depression has also been associated with 5HTTLPR low 
functioning polymorphism (9). Such association has then been tested and confirmed beyond 
environmental factors or genetics per se, providing evidence of a gene by environment mechanism 
involving 5HTTLPR polymorphism and SE as causal factor for affective disorders(55, 56). As 
regards Eating Disorders (ED), several pieces of evidence suggest a role of SE in the pathogenesis of 
these severe conditions(57, 58). Conversely, the low functioning 5HTTLPR S allele does not seem 
to be associated with ED, according to the meta-analysis we published in World Journal of Biological 
Psychiatry(28), recently confirmed by a systematic review. This latter recent systematic review by 
Rozenblat et al (46) additionally focused on ED risk and 5HTTLPR by SE interaction. It showed that 
two studies found a 5HTTLPR by traumatic life events association with disordered eating, but only 
one found an association with Anorexia Nervosa (AN) diagnosis (40, 59, 60). Moreover in this latter 
study (40) the 5HTTLPR by SE association only included risky parenting style as SE, excluding 
milder trauma definitions, which could not interact with 5HTTLPR polymorphism instead. Furtherly 
complicating the big picture, considering only sexual abuse as SE, one study found ED symptoms, as 
reated by specific scales, depending on a 5HTTLPR by SE interaction, while other authors did not 
replicate the same finding (15). In line with the aforementioned systematic review (46) we aimed to 
investigate the association of 5HTTLPR and SE with ED beyond the two risk factors separately (see 
above), testing a gene by environment model on ED similarly to what has been tested in depression.   
3.2 METHODS 
Sample and Questionnaires. We included 141 controls and 686 patients with life-time diagnosis of 
ED. Patients were divided in 181 AN Restricters, 38 AN Purging type, 31 Bulimia Nervosa (BN) 
Non Purge, 159 BN Purging type, 277 Eating Disorder Non Otherwise Specified (EDNOS). Patients 
have been recruited in 5 Eating Disorders specialized centers in Veneto region in the context of 
Bio.Ve.D.A. (BIobanca VEneta per i Disturbi Alimentari) (see above). Inclusion criteria were a life-
time diagnosis of AN, BN, EDNOS according to DSM-IV(32), age older than 14 years old, patients’ 
and parental (if less than 18 years old) informed consent. Exclusion criteria were comorbidity with 
organic or other psychiatric disorders. The presence of stressful events has been investigated in all 
participants through a list including partner separation or divorce, study or work related failures, city 
moving, environment, social or familiar conflictuality, death of significant others, abortion, violence 
or sexual abuse, severe medical sickness. Their date of occurrence and subjective severity scoring 
from 1(mild) to 5 (severe) were collected.  The DNA sampling has been performed as described 
above (Chapter 2).  
Statistical analysis. We investigated the association between S-allele and ED or AN or BN using chi-
square test (2), in order to understand if 5-HTTLPR polymorphism had a pathogenetic role by his 
own (see above). Gene by environment hypothesis has been preliminarily studied dividing the sample 
in patients with and without S allele, through 2 and Mantel-Haenszel; independent variables were 
stress before age 12, and 5HTTLPR low functioning allele, while dependent variable was the presence 
of an ED. The same analysis has been performed considering stress before 18 years instead of 12 
years age. In addition, we tried to assess if mild, moderate, and severe SE differently contributed to 
ED risk, in both groups with and without S allele, via a logistic regression to test the 5HTTLPR by 
SE interaction according to the multiplicative model. We tested if S-allele increased perception of 
severity of stressful events. Finally we tested a 5HTTLPR by SE additive interaction model using the 
Relative Excessive Risk due to Interaction (RERI) (61). 
3.3 RESULTS. 
Participants. Mean BMI of the 117 HC was 21.76 (3.12) Kg/m2, mean age 25.42(5.75) years old; 
mean BMI of 686 patients with ED was 19.14 (3.85) Kg/m2, mean age was 24.89 (8.84) years old. In 
patients with AN minimum BMI was 15.11 (1.96) Kg/m2, while in BN minimum BMI was 20.12 
(3.1) Kg/m2. 
Stressful events and 5HTTLPR polymorphism. No significant association was found. 
Childhood stressful events, and S allele. Our results show an increased risk of both AN (OR=1.84, 
95%CI 1.17-2.91, p=0.009)  and BN (OR=2.08, 95%CI 1.30-3.35, p=0.002) in subjects experiencing 
severe stressful events in childhood, regardless the 5HTTLR genotype. Dividing the sample 
according to S allele, when the same analyses were run in patients without S allele, no such 
association was found, which in turn was confirmed in patients with S allele (tab 5). 
Life-time stressful events according to severity, and S allele. Our results show an increased 
association of ED, and of AN and BN separately, with lifetime stressful events. The relationship was 
significant regardless the 5HTTLPR genotype, and also considering patients with or without S allele 
separately. More severe stressful events conferred higher risk of ED. 
Correlations. Regardless 5HTTLPR polymorphism, minimum life-time Body Mass Index (BMI), age 
of onset, EDI drive for thinness, body shape concerns, and ineffectiveness, self-esteem, alongside 
with obsessive-compulsive, depression and anxiety comorbidity correlated with the number of SE 
experience. Age of onset, ineffectiveness, self-esteem, alongside with obsessive-compulsive, 
depression and anxiety comorbidity correlated with the number of childhood SE. When considering 
patients without S allele, only age of onset, body shape concerns, and ineffectiveness remained 
significantly correlated with life-time or childhood SE, while considering those with S allele 
minimum life-time BMI, age of onset, EDI drive for thinness, body shape concerns, and 
ineffectiveness, self-esteem, alongside with obsessive-compulsive, depression and anxiety 
comorbidity remained significant. 
5HTTLPR by SE and risk of ED. According to logistic regression the risk of ED according to severity 
of stress was less increased in patients with no S allele (β=4.81, 95%CI 1.68-13.74, p=0.003), 
compared to those with S allele (β=9.17, 95% CI 4.02-20.89, p<0.001), and the same direction and 
magnitude of results were replicated when analyzing separately patients with AN and BN. However 
we did not find any 5HTTLPR by SE multpicative or addidtive interaction. 
3.4 DISCUSSION 
Our results add to the available evidence about 5HTTLPR by interaction SE model in ED, recently 
reported in an important recent systematic review and meta-analysis (46). We found a significant 
correlation of specific ED psychopathologic symptoms, such as drive for thinness, body shape 
concerns, perceived ineffectiveness, and of obsessive and depressive comorbidity with S allele, in 
presence of SEs. Also, wWhile 5HTTLPR and milder or single life events are not individually 
associated with ED, suffering from childhood SE and more severe SEs increases the ED risk. 
Moreover, while having a low functioning allele seems to expose patients who suffered from severe 
SE to an increased risk of ED, such an interactioin has not been confirmed according to either the 
gene by environment interaction multiplicative or additive model in ED. Such a different results from 
the above emntined recent systematic review and MA, could be due to the fact that we included full 
diagnoses ED only according to DSM-IV(32), and not only to possibly subclinical subjects. Thus, 
while ED symptoms could be linked to a 5HTTLPR by SE multiplicative or additive interaction, 
possibly in comorbidity with other psychiatric disorders, in particular depressive disorder, ED tout 
court do not seem to have such an interaction underpinning its pathogenesis. We nonetheless confirm 
that 5HTTLPR does not interact with SE according to any additive model, as previously suggested 
from Rozenblat(46). This moderates any conclusion about a real gene by environment interaction 
involved in the pathogenetic pathway of ED, since the additive interaction model measures, RERI, is 
supposed to better explain and to be more sensitive to identifying gene by environment interactions 
in biology (additive model) compared with other models.  
Beyond any causal inference, these data can be relevant at a patient level. For example, if clinicians 
know that a patient is an S-allele carrier, depressive and obsessive comorbid conditions should be 
suspected, and patients should be monitored for eventual emerging of such disorders beyond the acute 
phase of any ED. Moreover, clinicians should account for those psychopathologic dimensions (drive 
for thinness, body shape concerns, ineffectiveness) that could persist even if weight and behavioral 
pathological phenomena required for an ED diagnosis are no more formally satisfied. We suggest 
that with such an approach, ED relapse, which is a common event in AN and BN, could eventually 
be prevented or at least moderated. Also, since comorbid conditions obstacle and make ED more 
resistant to classic therapeutic tools, a proper detection of eventual depressive and obsessive 
symptomatology should be warranted. Finally, in the context of cognitive-behavioral psychotherapy 
or family therapy, if thanks to the 5HTTLPR genotyping a therapist since the very beginning of the 
treatment suspects dominant specific psychopathologic domain, we suggest better or faster results 
could eventually be achieved. However such an effect of the use of 5HTTLPR gemotyping in clinical 
activity should be investigated with ad hoc designed studies. 
Our study has several strength points. First of all the sample size is large and provides reliable and 
solid results. Secondly, we assessed SE with a structured interview, minimizing the subjective 
component in reporting ESs. Third, we also excluded the possibility to have a biased recall of SE in 
low or high functioning 5HTTLPR  genotypes, since we did not find any association between S allele 
frequency and number of SEs. Fourth, we included both full criteria standardized diagnosed ED, and 
ED psychopathology measures, such as EDI as well. Finally, our results are at essentially in line with 
the more recent and large MA investigating the 5HTTLPR by SE interaction model in ED, at least as 
regards the absence of an additive interaction. 
Several limitations should be mentioned as well. We only included female subjects;  however this is 
due to gender asymmetric distribution of ED. Secondly, we did not distinguish between restrictive 
and purging AN, or between purging or non-purging BN. Also, we did not consider Binge Eating 
Disorder at all, since we mainly focused on AN and BN. Finally, our SE related information were 
collected with a retrospective design. Even if we tried to minimize it, the retrospective design could 
have introduced some recall-biased information. 
In conclusion our results suggests that 5HTTLPR polymorphism may moderate the effect of SEs in 
increasing the risk of ED onset. Moreover the absence of S allele seemed to moderate the influence 
of SEs on ED severity, anxious, depressive and obsessive symptoms. However when we tested a 
multiplicative interaction, and an additive model, which is considered to be more representative of a 
real-world gene by environment interaction, the 5HTTLPR by SE interaction was not confirmed. 
 
 
  Any Stressful Event OR IC 95% 
Controls (141) S Allele =0 (42) 21,4% (9)   
S Allele =1 (99) 20,2% (20)   
Eating Disorders (679) S Allele =0 (198) 34,8% (69) 1,96 (p=0,096) 0,89 - 4,33 
S Allele =1 (481) 34,3% (165) 2,06 (p=0,007) 1,22 - 3,49 
AN (422) S Allele =0 (112) 36,6% (41) 2,12 (p=0,077) 0,92 - 4,86 
S Allele =1 (310) 31,0% (96) 1,77 (p=0,040) 1,03 - 3,06 
BN (288) S Allele =0 (87) 31,0% (27) 1,65 (p=0,257) 0,69 - 3,92 
S Allele =1 (201) 36,3% (73) 2,25 (p=0,005) 1,28 - 3,99 
 
Tab 5. Stressful events and risk of Eating Disorders, according to 5HTTLPR polymorphism. 
  
4.  NEUROPSYCHOLOGICAL PERFORMANCE AND 5HTTLPR IN EATING 
DISORDERS 
4.1 INTRODUCTION 
Several psychiatric disorders, such as major depressive disorder (MDD), bipolar disorder (BD), and 
schizophrenia are associated with deficitary cognitive functions. More in particular MDD with 
psychotic symptoms has shown a deficit in verbal and visual learning, and executive functions(62), 
as depression with melancholic features did(63). Moreover both BD and schizophrenia are associated 
with poor cognitive performance, more severly in schizophrenia, and in patients with early onset of 
disease, in several domains(64). Patients with Anorexia Nervosa (AN) have shown a lower 
performance in several neuropsychological functions compared to healthy controls as well. A wide 
range of cognitive functions performance have been questioned in eating disorders (ED); cognitive 
flexibility, set-shifting, central coherence and even theory of mind seems to be impaired specifically 
in AN(65). In this context we recently showed that  patients affected by ED have a lower performance 
at Cognitive Bias Task (66) independently from general psychopathology, education, handedness and 
ED diagnostic subtypes, compared to age and gender matched subjects without psychiatric condition. 
Also, our research group showed that patients with AN had poorer central coherence (defined as the 
ability to prioritize the “big picture” instead of small details), and poorer set-shifting (defined as the 
ability to update decisions according to environmental updated rules) compared to healthy controls 
(HC), and that this defect also involved patients’ unaffected siblings (67), possibly indicating a 
cognitive endophenotype of AN. Also patients with bulimia nervosa (BN) appear to have a lower 
decision making performance as measured by Iowa Gambling Task, but the differences with HCs 
were more pronounced in BN group with previous AN (68). Similarly, set-shifting function abilities 
measured with Wisconsin Card Sorting Test were lower only in patients affected by both BN and 
previous AN, thus suggesting a predominant role of life-time AN on cognitive alterations in ED (68), 
rather any ED or rather than BN in particular. 
Given the aforementioned body of evidence, and given the fact that cognitive functions has been 
interestingly suggested as a phenotype with a strong enetic background in ED (69), several authors 
have also investigated the role of 5HTTLPR in neuropsychological performance. Among others data 
from our group in University of Padua(66) have also shown that 5HTTLPR polymorphism impacts 
on decision making. In particular, our data showed that patients with low functioning genotypes had 
a poorer performance at Cognitive Bias Task, revealing an external context-independent perseverant 
decisional process in these subjects. 
4.2 METHODS 
Participants and genotyping. We included 227 patients with AN and 198 HCs. 5HTTLPR 
polymorphism genotyping has been previously described. We collected information about the 
minimum life-time BMI. All patients were affected by ED, according to DSM-IV (32).  
Neuropsychological assessment. Patients were administered with the following tests. Edinburgh 
Handedness Inventory (a scale to measure the dominance of a person’s right or left hand in everyday 
activities) (70), Wisconsin Card Sorting Test (a test where participants are told to match the cards, 
are not told how to match them, but are told if the matching is right or wrong, according to rules that 
continue to change - it determines set-shifting abilities), Trail A making test, Trail B making test (for 
visuo-spatial abilities and cognitive flexibility – in trail making A the subject is required to connect 
a set of 25 numbered dots (1,2,3,4…) as quickly and accurately as possible, in trail making B the 
subject has to alternate numbers and letters (1,A,2,B,3,C…)) (71), Iowa Gambling Task (attempts to 
simulate real-life decision making offering the participant 4 card sets, each associated with different 
money gain in the long run; the subject is asked to win as much money as possible), Cognitive Bias 
Task (measures how the decision-making is influenced by internal or external information, and how 
perseverative it is).  
Statistical analyses. We used the t-test for independent samples to determine if performance at the 
above mentioned neuropsychological functions differed between patients with low functioning 
5HTTLPR S allele and patients without it. 
4.3 RESULTS  
Participants. Among patients, 173 had the low functioning genotype, and 54 had the high functioning 
one. Minimum life-time BMI was significantly lower in patients with 5HTTLPR S allele compared 
to those with high functioning genotype (p=0.007) 
Trail making test. Trail B making test and the difference between Trail A and trail B making test 
performance were significantly impaired in patients with S allele (p=0.009, p=0.046).  
Cognitive Bias task. Patients with S allele had a significantly worse performance in CBT, compared 
with patients with high functioning genotype. These results are consistent with our results from a 
smaller population, previously published (66).  
Iowa Gambling Task, Wisconsin Card Sorting test, Edinburgh Handedness Inventory. No significant 
difference was found according to 5HTTLPR polymorphism. 
4.4  DISCUSSION 
Our results show that 5HTTLPR polymorphism plays a role in neuropsychological functions in 
patients with AN, with S allele determining a worse performance in environment dependent decision 
making process, and worse cognitive flexibility. Also, our results show how having 5HTTLPR S 
allele is associated with a life-time lower BMI. 
Our positive results regarding cognitive bias task could suggest that a more internally based decisional 
process, less linked to external contexts, thus to reality, could play a role in ED pathogenesis and/or 
maintenance. Patients affected by both AN and BN often do not seek for help in fact, and in some 
severe cases refuse treatment, despite severe comorbid organic life-threatening complications. It 
could be argued that even if they understand medical information about the eventually dramatic 
prognosis of their condition, they are not allowed to decide according with external inputs, due to the 
internally driven perseverative decisional process underpinning their behavior. Thus, due to this 
perseverative error and defect of adaptive choices given a set of factual environmental information, 
it is possible that patients only engage in any treatment only once more severe status is reached, 
included a lower BMI or organic complications. 
Moreover, S allele moderating Trail making B test could suggest that patients with the low 
functioning polymorphism may have a lower ability to “reset” or change the extremely strict thoughts  
that influence their daily behaviors, and may experience far more difficulties in interrupting the ED 
cognitive and behavioral loop that mantains the disease. 
We also described no influence of 5HTTLPR alleles in set shifting and decision making abilities; 
while S allele has been described mediating worse decision making in suicide attempters (72) and 
cannabis users(73), it may be argued that a peculiar disease specific interaction between genes and 
cognitive functions could  result in different phenotypes in different diseases. Moreover, differently 
from all other psychiatric disorders, Ed and AN in particular are associated with clinically relevant 
weight alterations. Hence it could be also argued that a lower BMI in turn moderates 
neuropsychological impairment, and that its influence may silent or overcome smaller effects due to 
toher factors such as genetic polymorphims; however only longitudinally designed studies could 
clarify this eventually bidirectional relation. 
These data and others from our group (66)furtherly suggest that 5HTTLPR polymorphism, even if 
not involved as causal factor per se(28), could play a role in the complex multifactorial maintaining 
loop of ED. Having a life-time AN diagnosis was associated with poor Cognitive Bias Task, which 
we suggest could increase the risk for less resilient behaviors and ED relapse. We believe that 
5HTTLPR genotyping could help clinicians in detecting those subjects with poorly adaptive decision 
making since the very first assessment, focusing more on decisional processing rather than other 
psychopathologic aspects, which are hardly susceptible of any improvement due to rigidity and 
perseverative internally driven behaviors which could maintain EDs, regardless the diagnostic 
subtype.  
 
 
  
5. BRAIN CONNECTIVITY, 5HTTLPR AND ANOREXIA NERVOSA 
5.1 INTRODUCTION 
Many factors have been associated to anorexia nervosa (AN) pathogenesis, and among these 
structural brain alterations as well. A large body of literaure has been published on functional (74) 
and structural(75) neuroimaging in AN. Several studies have shown that during acute phase of AN, 
both grey matter (GM) and white matter (WM) are decreased in volume, but that this volumetric 
reduction encounters a “restitutio ad integrum” after weight recovery. However too few longitudinal 
studies included healthy patients suffering from Anorexia Nervosa afterwards, thus it’s still debated 
whether structural brain alterations in AN are only linked to malnutrition, dehydration or weight loss, 
or if they occur before and determine the weight loss itself. Actually, only few structural studies 
considered comorbid diagnoses which could decrease specific brain areas, medications, hydratation 
(76), and total intracranial volume; a recent meta-analysis has defined results about structural 
alteration in AN as “inconclusive” (77).  More solid conclusions have been drawn about functional 
magnetic resonance in AN, with emotion and food processing related neural pathways showing some 
consistent degree of alteration across studies, in particular in amygdala (74). 
Brain connectivity can be considered one of the most complex systems in nature. But, differently 
from other systems in nature, brain has a specific structure, with each anatomical region supposedly 
linked to a specific function occupying a precise position. Due to the fact that systems in nature often 
do not behave according to specific spatial borders (78) thus increasing a system’s complexity, the 
brain could reveal as a favorable field to apply complex network model analysis. Briefly, a network 
can be defined as a mathematical representation of a real world complex system (79), defined by a 
collection of nodes and links between pair of nodes. Links can be thought as connections between 
different brain areas, in a large scale approach. They can be either binary/anatomical (white matter 
tracts), functional (temporally related activities in different brain regions) (80), or effective (direct or 
indirect causal relation between two areas that may be estimated from observed perturbations)(81). 
If we apply this model to the brain, the choice of nodes should ideally be well motivated on the base 
of solid anatomical or functional a priori criteria, should include the entire brain, and should not 
divide it into overlapped regions (82). On the other hand, while binary anatomical connections are 
either present or absent, functional and effective connectivity always need to be filtered via a 
weighted threshold, necessary to remove noise and other unrelated signals (83). Roughly, nodes and 
connections can be studied through three main sets of measure: functional segregation, functional 
integration, and small-world brain connectivity. Functional segregation can be defined as the ability 
for specialized processing to occur within densely interconnected groups of brain regions (79). Local 
efficiency (measure of a network’s tendency to create subgroups of strongly interconnected elements) 
and modularity (estimates of how a network includes many links connecting nodes within a module, 
and few links among modules) are two indexes of segregation. Global efficiency (topological estimate 
of distance between graph’s elements) is a measure of integration. Sigma or “small-worldness” is the 
ratio between mean normalized clustering coefficient and mean normalized path, and stands for the 
efficiency at which information can be processed. 
The aim of this study is to test the effect of 5HTTLPR polymorphism on MR acquired brain 
connectivity data, in consideration of neuro-cognitive altered functions in AN (see above, chapter 4).  
In this context we are also creating a multimodal database containing neuroimaging, 
neuropsychological, biological, and genetic data from Bio.Ve.D.A.  
5.2 METHODS 
Participants and genotyping. A sample of 74 subjects (38 healthy controls (HC), 36 AN) were 
scanned with 1.5 Tesla MR. 5HTTLPR polymorphism genotyping has been previously described. 
Low functioning genotypes were the majority in both HCs (26 out of 38 participants) and in patients 
with AN (29 out of 36 participants). 
Magnetic resonance. A 1.5 Tesla MR tool was used. The following sequences were acquired: 1) T1 
brain scan for high resolution structural brain images , 2) T2/FLAIR to detect eventual structural 
lesions, 3) BOLD sequences to  analyze functional connections among brain areas. 
Network construction:  The Graph Analysis Toolbox (GAT) was used to compute network analysis. 
We parcellate the brain in 128 cortical and subcortical non-overlapping areas with freesurfer in order 
define the network nodes. The coordinates for these regions were determined using the Destrieux 
Atlas.  To construct a connectivity matrix for each subject, we extracted the regional mean time series 
for each node and calculated Pearson correlations between all pairs. Correlations on the diagonal of 
the connectivity matrix were set to zero. In order to avoid the possible confounding that may result 
from the application of an absolute threshold, we applied a range of proportional thresholds to each 
individual association matrix to compare the network topologies across that range. Age and 
Edinburgh Handedness Inventory scores are used as covariates.  
Network measures: Segregation properties of the network are measured with modularity coefficient 
and local efficiency. Modularity is evaluate by subdividing the network into groups of regions that 
have maximal within group connections and minimal between-group links. The quantification of 
modular structure is optimized with GN algorithm. Local efficiency of a node is the inverse of the 
average shortest path connecting all neighbors of that node and represent a measure of the clustering 
properties of the network. Integration properties of the network are measured with global efficiency, 
computed as the average inverse shortest path length in the network. The Small World property of 
the network is computed as the ratio between clustering coefficient and the characteristic path length, 
normalized to the corresponding values of a random graph with the same number of nodes, links and 
degree of the nodes. 
5.3 RESULTS 
Participants characteristics. Mean age of HC was 25.3+6.3 years old, and mean BMI was 19.6+1.6 
Kg/m2. Mean age of patients with AN was 26.1+7.2years old, and mean BMI was 15.8+1.8 Kg/m2. 
Integration measures. No difference was found about global efficiency in both HC and patients with 
AN according to 5HTTLPR polymorphism. 
Segregation measures. S allele tended to a significant association with higher modularity (p=0.07), 
and local efficiency (=0.11) compared with high functioning genotype in HC. On the contrary in 
patients with AN, S allele tended to confer a lower modularity (p=0.1) and lower local efficiency 
(p=0.1) compared with high functioning genotypes (fig 5, 6, 7). 
Small-worldness measures. S allele tended to a significant association with higher sigma (small world 
network) (p=0.051), compared with high functioning genotypes. On the contrary in patients with AN, 
S allele conferred a lower sigma (p=0.003) compared with high functioning genotype (fig 8). 
5.4  DISCUSSION 
Our results suggest that S allele confers a lower segregation in connectivity in patients with AN with 
a low functioning genotype, while a higher segregation in HCs on the contrary. Despite preliminary 
nature of our data, and the poor available literature focusing on graph theory applied to brain 
connectivity of AN, several considerations should be made when discussing our results. First of all it 
must be mentioned that despite the small sample size, here we replicate findings from Servaas (84) 
and the Groningen group of Neuroimaging group in collaboration with Cambridge Cognition and 
Brain Sciences Unit, which recruited 120 women and found a higher segregation in subjects carrying 
the 5HTTLPR S allele. Authors suggest that in healthy subjects with S allele, poorer cognitive control 
subnetworks connections with other brain areas could explain attentional bias (85) and increased 
emotional reactivity (86), which in turn could explain some of the associations between 5HTTLPR 
low functioning genotype and several psychiatric disorders listed in the introduction of this final 
dissertation, such as borderline personality disorders, and antisocial behavior.  
However our observations seem to suggest a different role of the 5HTTLPR genotype in mediating 
the functional brain network architecture between AN patients and healthy controls. Such a difference 
is of great interest considering the role of serotonin transporter in the regulation of emotional and 
behavioural control processes, in executive functioning and in the modulation of cortico-limbic 
circuits. Serotoninergic pathways are indeed crucial for the coupling between cognitive and emotional 
processes and therefore, on the basis of our data, we can suppose that the hypothesized impaired 
balance between bottom up and top down circuits that characterize the neurobiology of AN could be 
partially moderated by 5HTTLPRpolymorphism. However the cross-sectional nature of our study 
doesn’t allow to identify if the 5HTTLPR genotype act more on the risk of developing the disorder 
or if it exerts a role in combination with the acute features of AN instead though (see limits section).  
Beyond AN, while both integration and segregation are necessary for the optimal functioning of a 
small-world network (87), modularity has been linked to a better response to cognitive training after 
brain injury (88), but to higher impulsivity(89) as well. Moreover while in autism spectrum disorder 
the S allele is associated with poorer default mode network connectivity, thus higher segregation, and 
in turn poorer social functioning in children and adolescents(90), higher modularity has been 
associated with better working memory (91) as well. While such information need to be replicated in 
further studies, and more importantly do not match our population of interest (AN), they provide an 
example of how the same connectivity alterations can yield positive or negative clinical implications, 
depending on the involved areas, the studied outcome, and the population of interest. Alongside with 
the whole brain analysis, more specific function-related networks should be a priori set as the object 
of interest to investigate integration and segregation in specific neuropsychological alterations or 
psychiatric disorders. While ideally integration of separate information coming from highly effective 
modules has been described as typical of HC compared with subjects affected by other psychiatric 
disorders(92, 93), proper segregation might be necessary for specific neuropsychological tasks 
beyond the whole brain degree of integration (91). Thus the lower segregation of the global 
connectivity network in AN patients with low functioning genotype is interesting since these patients 
show impaired executive functioning and a life time lower BMI. If modular network architecture 
provides greater resilience capacities if compared to more integrative functional patterns, and is more 
economic from an energetic and a metabolic point of view, we can hypothesize that the capacity to 
modulate the functional network in a more clustered fashion can be really important in a disorder 
with high energy-saving needs in order to advantageoulsy adapt the emotional, cognitive and 
behavioral responses to the environmental needs. The failure of S carriers patients in operating an 
effective modular reorganization of the network in the presence of starvation and malnutrition could 
underpin a disfunctional unbalance between emotional and cognitive control processing that can lead 
to difficulties in adaptive responses selection processes. We can assume that these compensatory 
difficulties can partially explain the greater inflexibility that characterizes those patients who show 
more resistances to conventional treatment plans and who might be candidates for more 
individualized treatment strategies.  Thus the lower network segregation in S carriers may be relative 
to a reduced compensatory capacity of the functional network in underweight conditions, with relative 
worsening of those performances for which a discrete and modular operations is necessary. 
Beyond the relevance of our findings in the long process of identification of biological mechanisms 
underlying clinical phenotypes in AN, our results may open the way for a deeper insight into the 
possible role of brain network analysis in the early screening for AN, or even in the identification of 
the at risk subjects. Similarly to what has been suggested in Alzheimer’s disease(94) where peculiar 
brain connectivity is described accordingly to the graph theory, magnetic resonance scanning could 
be used, in association with 5HTTLPR polymorphism for diagnostic or prognostic aims in the future. 
Moreover in both Alzheimer’s disease (95) and schizophrenia (96) brain connectivity as measured 
accordingly to graph theory, results impaired since pre-clinical or ealry stages of the disease. However 
only studies with longitudinal designs will show whether the results we are showing will extend to at 
risk subjects, or in other words whether they are a trait disease pre-existing condition or a state under-
weight immanent alteration. 
The present study has two main points of strength. First of all it is one of the first studies which 
investigates brain connectivity according to the graph theory in AN. Secondly, it also investigates the 
role of 5HTTLPR polymorphism, following a multimodal research approach which provides far more 
information beyond each single research approach per se. 
However several limitations should be mentioned as well. The main limitation is the small sample 
size, which is due to the pilot nature of the study and its preliminary phase. This limited the statistical 
significance of our results, which however had a solid and consistent trend towards an effect of 
5HTTLPR on brain connectivity in AN. Secondly, patients were scanned with 1.5 Tesla MR device, 
while 3Tesla would have provided data from higher resolution scans. However 1.5 Tesla devices are 
still widely used in research. Third, the study had a cross-sectional design; thus any causal or 
prognostic consideration was not allowed. Fourth, we only included patients with AN, excluding 
those affected by BN. However due to pilot nature of our investigation we chose to focus on the 
diagnostic group where more solid evidence was available about neuropsychological functioning, and 
this was the AN case. Fifth, we here report the whole brain analysis results; however we also ran the 
subnetwork analyses which however did not yield any significant result. 
In conclusion, even if 5HTTLPR does not seem to play a role in AN onset (28), it does play a role in 
its specific neuropsychological functions(66), and this study suggests a neural connectivity substrate 
underpinning such alterations. 
 
 
 
 
Fig 5. Mean Local Efficiency and 5HTTLPR polymorphism in healthy controls and anorexia nervosa. 
 
Fig 6. Modularity and 5HTTLPR polymorphism in healthy controls and anorexia nervosa. 
 
 Fig 7. Brain connectivity in patients with anorexia nervosa and 5HTTLPR low functioning genotype. 
 
Fig 8. Sigma “small-worldness” and 5HTTLPR polymorphism in healthy controls and anorexia 
nervosa. 
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